Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin

Biochimica et Biophysica Acta - General Subjects

Volumn 1830, Issue 3, 2013, Pages 2790-2797

  Berge, Elisabet O ^a,b   Huun, Johanna ^a,b   Lillehaug, Johan R ^a   Lønning, Per E ^a,b   Knappskog, Stian ^a,b  

^a UNIVERSITY OF BERGEN   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast; Cancer; Mutation; p53; Resistance

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BETA GALACTOSIDASE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; MITOMYCIN; MUTANT PROTEIN; PROTEIN P53; PROTEIN VARIANT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER LOCALIZATION; CELL GROWTH; CELL NUCLEUS; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; NICK END LABELING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENESCENCE; SOMATIC MUTATION; TREATMENT RESPONSE; WILD TYPE;

ANTHRACYCLINES; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; BIOPSY; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOMYCIN; MUTATION; PLASMIDS; PROTEIN BINDING; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION, GENETIC; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84873577850     PISSN: 03044165     EISSN: 18728006     Source Type: Journal    
DOI: 10.1016/j.bbagen.2012.12.004     Document Type: Article

References (28)

1. K.H. Vousden, and X. Lu Live or let die: the cell's response to p53 Nat. Rev. Cancer 2 2002 594 604
2. W.S. el-Deiry Regulation of p53 downstream genes Semin. Cancer Biol. 8 1998 345 357
3. W.S. el-Deiry, S.E. Kern, J.A. Pietenpol, K.W. Kinzler, and B. Vogelstein Definition of a consensus binding site for p53 Nat. Genet. 1 1992 45 49
4. N.A. Barlev, L. Liu, N.H. Chehab, K. Mansfield, K.G. Harris, T.D. Halazonetis, and S.L. Berger Acetylation of p53 activates transcription through recruitment of coactivators/histone acetyltransferases Mol. Cell 8 2001 1243 1254
5. K. Oda, H. Arakawa, T. Tanaka, K. Matsuda, C. Tanikawa, T. Mori, H. Nishimori, K. Tamai, T. Tokino, Y. Nakamura, and Y. Taya p53AIP1, a potential mediator of p53-dependent apoptosis, and its regulation by Ser-46-phosphorylated p53 Cell 102 2000 849 862
6. Y. Samuels-Lev, D.J. O'Connor, D. Bergamaschi, G. Trigiante, J.K. Hsieh, S. Zhong, I. Campargue, L. Naumovski, T. Crook, and X. Lu ASPP proteins specifically stimulate the apoptotic function of p53 Mol. Cell 8 2001 781 794
7. S. Kato, S.Y. Han, W. Liu, K. Otsuka, H. Shibata, R. Kanamaru, and C. Ishioka Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis Proc. Natl. Acad. Sci. U. S. A. 100 2003 8424 8429
8. A. Petitjean, M.I. Achatz, A.L. Borresen-Dale, P. Hainaut, and M. Olivier TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes Oncogene 26 2007 2157 2165
9. S. Geisler, A.L. Borresen-Dale, H. Johnsen, T. Aas, J. Geisler, L.A. Akslen, G. Anker, and P.E. Lonning TP53 gene mutations predict the response to neoadjuvant treatment with 5-fluorouracil and mitomycin in locally advanced breast cancer Clin. Cancer Res. 9 2003 5582 5588
10. R. Chrisanthar, S. Knappskog, E. Lokkevik, G. Anker, B. Ostenstad, S. Lundgren, E.O. Berge, T. Risberg, I. Mjaaland, L. Maehle, L.F. Engebretsen, J.R. Lillehaug, and P.E. Lonning CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer PLoS One 3 2008 e3062
11. S. Geisler, P.E. Lonning, T. Aas, H. Johnsen, O. Fluge, D.F. Haugen, J.R. Lillehaug, L.A. Akslen, and A.L. Borresen-Dale Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Res. 61 2001 2505 2512
12. J.L. Hayward, P.P. Carbone, J.C. Heusen, S. Kumaoka, A. Segaloff, and R.D. Rubens Assessment of response to therapy in advanced breast cancer Br. J. Cancer 35 1977 292 298
13. J.E. Chipuk, and D.R. Green p53's believe it or not: lessons on transcription-independent death J. Clin. Immunol. 23 2003 355 361
14. C.A. Schmitt, J.S. Fridman, M. Yang, S. Lee, E. Baranov, R.M. Hoffman, and S.W. Lowe A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy Cell 109 2002 335 346
15. N.P. Gomes, and J.M. Espinosa Differential regulation of p53 target genes: it's (core promoter) elementary Genes Dev. 24 2010 111 114
16. J.M. Morachis, C.M. Murawsky, and B.M. Emerson Regulation of the p53 transcriptional response by structurally diverse core promoters Genes Dev. 24 2010 135 147
17. M.A. Resnick, and A. Inga Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity Proc. Natl. Acad. Sci. U. S. A. 100 2003 9934 9939
18. D. Menendez, A. Inga, and M.A. Resnick The biological impact of the human master regulator p53 can be altered by mutations that change the spectrum and expression of its target genes Mol. Cell. Biol. 26 2006 2297 2308
19. D. Kandioler-Eckersberger, C. Ludwig, M. Rudas, S. Kappel, E. Janschek, C. Wenzel, H. Schlagbauer-Wadl, M. Mittlbock, M. Gnant, G. Steger, and R. Jakesz TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin. Cancer Res. 6 2000 50 56
20. P.E. Lonning Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance Trends Mol. Med. 10 2004 113 118
21. S.E. Kern, J.A. Pietenpol, S. Thiagalingam, A. Seymour, K.W. Kinzler, and B. Vogelstein Oncogenic forms of p53 inhibit p53-regulated gene expression Science 256 1992 827 830
22. J. Milner, and E.A. Medcalf Cotranslation of activated mutant p53 with wild type drives the wild-type p53 protein into the mutant conformation Cell 65 1991 765 774
23. S. Srivastava, S. Wang, Y.A. Tong, Z.M. Hao, and E.H. Chang Dominant negative effect of a germ-line mutant p53: a step fostering tumorigenesis Cancer Res. 53 1993 4452 4455
24. D.R. Green, and G. Kroemer Cytoplasmic functions of the tumour suppressor p53 Nature 458 2009 1127 1130
25. M. Ferrone, F. Perrone, E. Tamborini, M.S. Paneni, M. Fermeglia, S. Suardi, E. Pastore, D. Delia, M.A. Pierotti, S. Pricl, and S. Pilotti Functional analysis and molecular modeling show a preserved wild-type activity of p53(C238Y) Mol. Cancer Ther. 5 2006 1467 1473
26. Y. Cho, S. Gorina, P.D. Jeffrey, and N.P. Pavletich Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations Science 265 1994 346 355
27. S. Rowan, R.L. Ludwig, Y. Haupt, S. Bates, X. Lu, M. Oren, and K.H. Vousden Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant EMBO J. 15 1996 827 838
28. P.E. Lonning Study of suboptimum treatment response: lessons from breast cancer Lancet Oncol. 4 2003 177 185